Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542


Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

EvaluatePharma Orphan Drug Report 2018

Worldwide orphan drug sales are forecasted to grow at a CAGR of 11% from 2018-2024

EvaluatePharma Orphan Drug 2018 Report EvaluatePharma Orphan Drug 2018 Report EvaluatePharma Orphan Drug 2018 Report

Download Report

Our 2018 Orphan Drug Report shows continuing unmet medical need is set to fuel the growth of the worldwide orphan drug market with sales predicted to grow at over 11% a year to $262bn by 2024. By 2024, orphan drugs will represent over a fifth of the worldwide prescription market.

Despite a slowdown in pricing, the report shows that the mean cost per patient per year still managed to hit $147,308 in 2017, more than four times the mean cost for non-orphan drugs at $30,708.

Key highlights:

  • The mean price of the top 100 USA orphan drugs is expected to grow at an annual rate of 5.2%
  • Revlimid forecasted to be the USA’s top selling orphan drug in 2024
  • Soliris generated the highest USA revenue per patient for orphan drugs in 2017
  • Expected strong sales of Revlimid and Pomalyst will secure Celgene’s position as 2024 worldwide leader
  • Lanadelumab is the most valuable orphan drug in R&D, with a Net Present Value of $7.48bn

              EvaluatePharma Orphan Drug 2018 Infographic

View Orphan Drug 2018 Infographic

Press Release

Confirm your details on form below to download this report